



ELSEVIER
SAUNDERS

Neurosurg Clin N Am 15 (2004) 565–584

NEUROSURGERY
CLINICS
OF NORTH AMERICA

Cumulative Index 2004

Volume 15

January	CLINICAL NEUROENDOSCOPY, pages 1–108
April	PERIPHERAL NERVE TUMORS: DIAGNOSIS AND MANAGEMENT, pages 109–256
July	PAIN TREATMENT, pages 257–364
October	METASTATIC SPINE DISEASE, pages 365–584

Note: Page numbers of article titles are in **bold face** type.

A

- Acoustical schwannomas, in neurofibromatosis type 2, 150–153
- Aesculap neuroendoscopes, 23–26
- Age factors, in third ventriculostomy outcome, 74–76
- Alcohol, for embolization, in metastatic spine disease, 397
- Allodynia
in neuropathic pain, 234
in peripheral nerve tumors, 125
neuroimaging of, 278–279
- AMGN-0001 (osteoprotegerin), for metastatic spine disease, 534
- Amitriptyline, for pain
in metastatic spine disease, 520
neuropathic, 235
- Amputation neuromas, 225–226
- Amygdala, pain perception in, 272–273
- Analgesics, conversion guide for, 523–524
- Androgen deprivation, for metastatic spine disease, 531
- Anesthesia, for metastatic spine disease surgery, 537
- Angina pectoris, spinal cord stimulation for, 300–301
- Angiography, in metastatic spine disease, 370
for embolization planning, 392
for lateral extracavitary approach, 438
- Angiolipomas, ulnar nerve compression by, 247
- Anterior approaches, to metastatic spine disease, **443–451**
cervical, **413–424**
complications of, 449–450
indications for, 444–446
patient selection for, 443–444
posterior stabilization with, 445, 449
retroperitoneal, 448
technique for, 446–449
thoracoabdominal, 447
transthoracic, 447
vertebrectomy in, 448
vertebroplasty in, 448–449
- Anticipation, of pain, 277
- Anticonvulsants
for pain
in metastatic spine disease, 518–519
neuropathic, 235
for trigeminal neuralgia, 319–321
- Antidepressants, for pain
in metastatic spine disease, 519–520, 523–524
neuropathic, 235
- Antoni A and B patterns, in schwannomas, 157–158
- Appendiceal neuromas, 228
- Aqueduct of Sylvius, occlusion of
CSF entrapment in, 84–85
third ventriculostomy for, 49–51, 73–74
- Arachnoid cysts, **9–17**
clinical presentation of, 10
complications of, 16

Arachnoid (*continued*)
 diagnosis of, 10–11
 frameless stereotactic systems for, 13–14
 intraventricular, 10–11
 laterally projecting, 13
 locations of, 10
 pathology and pathogenesis of, 9–10
 shunting of, 15
 suprasellar, clinical presentation of, 10
 treatment of, 4, 11–16

Arachnoid granulations, obstruction of, 48

Aromatase inhibitors, for metastatic spine disease, 530–531

Asystole, in third ventriculostomy, 69

Attention, pain perception and, 276–277

Auer Neuro-Endoscope, 23–24

Autonomic nervous system
 dysfunction of
 in peripheral nerve tumors, 126
 pain with, spinal cord stimulation for, 302
 spinal cord stimulation effects on, 300

Axial pain, in metastatic spine disease, 403

B

Back pain
 in metastatic spine disease. *See* Pain, in metastatic spine disease.
 spinal cord stimulation for, 302–303

Baclofen
 for intrathecal analgesia, opioids with, 292
 for trigeminal neuralgia, 320

Balloon compression, for trigeminal neuralgia, 326

Basal cell carcinoma, metastasis from, to brachial plexus, 249

Basal ganglia, pain perception in, 272–273

Basilar artery, in third ventricle
 anatomy of, 41
 injury of, in third ventriculostomy, 63, 69–70

Batson's plexus, metastasis transmission through, 365

Biologic therapy, for malignant peripheral nerve sheath tumors, 208–209

Biologically effective dose, in radiotherapy, 473

Biomechanics, of metastatic spine disease, 375–380

clinical applications of, 378–379
 regional nuances in, 376–378

Biopsy, of tumors
 endoscopic, 4, 100–101
 paraspinal, 220
 peripheral nerve
 errors in, 194–196
 malignant, 205
 spinal, 370–371

Bisphosphonates, for metastatic spine disease, 406–407, 531–532, 551–552

Bleeding. *See* Hemorrhage.

Blood flow, stimulation of, spinal cord
 stimulation for, 299–300

Bone cement, for metastatic spine disease, 408, 415–423, 460

Bone graft, for metastatic spine disease, 415–416

Bone scan, in metastatic spine disease, 368, 381, 529

Brachial plexus, tumors of
 basal cell carcinoma metastasis, 249
 desmoid, 244–246
 neurofibroma, 183–184
 schwannoma, 182–183
 surgery for, 171–174, 179

Bradycardia, in third ventriculostomy, 69

Brain
 deep stimulation of. *See* Deep brain stimulation.
 tumors of. *See* Tumor(s), brain.

Brain stem, in pain pathway, 261
 functional imaging of, 274, 276

Breast carcinoma, metastatic to spine, medical management of, 532

Brown-Séquard syndrome, in metastatic spine disease, 367

Bugbee Wire, for hemostasis, 27

Bupivacaine, for intrathecal analgesia, opioids with, 292–293

NButyl cyanoacrylate, for embolization, in metastatic spine disease, 397

C

Café-au-lait macules, in neurofibromatosis, 147, 151–152

- Cage-chest tube construct, for metastatic spine disease, 419–420
- Calcitonin gene-related peptide, in pain pathway, 258, 262
- Calcium abnormalities, in metastatic spine disease, 530
- Cameras, for endoscopy, 21
- Cancer. *See also* Malignant peripheral nerve sheath tumors.
 in neurofibromatosis, 146–147, 209
 in peripheral nerve tumors
 recurrence of, 200–201
 surveillance for, 197
 in schwannomas, 159
 metastasis of. *See* Metastasis; Metastatic spine disease.
- Capecitabine, for metastatic spine disease, 531
- Carbamazepine, for trigeminal neuralgia, 319
- Carney's complex, 159
- Carpal tunnel syndrome
 in lipofibromatous hamartoma, 229–230
 surgery for, 117–118
- Catheter, peel-away, for endoscopy, 22
- Cauterization, equipment for, 27–28
- Cell survival curve, in radiotherapy, 467–468
- Cellular schwannomas, 159
- Cement, for metastatic spine disease, 408, 415–423, 460
- Central sensitization, in neuropathic pain, 261–263
- Centrolateral nuclei, thalamic, destruction of, for chronic pain, 337–338
- Centromedian nuclei, thalamic, destruction of, for chronic pain, 337–338
- Cerebellum
 anatomy of, 42–43
 developmental anatomy of, 35
 pain perception in, 272–273
 vermis of, agenesis of, 43
- Cerebral aqueduct, anatomy of, 42
- Cerebral arteries, injury of, in third ventriculostomy, 69–70
- Cerebral cortex
 in pain pathway, 260, 272–273
- stimulation of, versus deep brain stimulation, 348–349
- Cerebrospinal fluid
 hydraulics of, 45–47
 leakage of, in third ventriculostomy, 67
 metastasis transmission through, 365, 386
- Cervical spine, metastatic disease of
 biomechanics of, 376–377
 surgery for, **413–424**
 coaxial double-lumen reconstruction in, 419
 CyberKnife, 495
 indications for, 413–414
 plate in, 418–419
 polymethylmethacrylate in, 416–423
 prosthesis in, 417–418
 techniques for, 414–416
 Telescopic Plate Spacer in, 420–423
 titanium interbody cage in, 419–420
- Channel neuroendoscope, 26
- Chavantes-Zamorano Neuro-Endoscope, 23–24
- Chemoneurolysis, glycerol, for trigeminal neuralgia, 324–326
- Chemotherapy
 for malignant peripheral nerve sheath tumors, 149, 208
 for metastatic spine disease, 406–407, 454–455, 531, 551–552
- Chiari II malformation, 43–44
 fourth ventricle malformation in, 43–44
 third ventricle malformation in, 42
 third ventriculostomy contraindicated in, 48–49
- Chip cameras, for endoscopy, 21
- Choristomas, neuromuscular, 230
- Choroid plexus
 anatomy of, 37, 57–58
 endoscopy of, 3
- Choroidal cysts, of lateral ventricle, 39–40
- Choroidal fissure, developmental anatomy of, 34
- Chronic pain
 ablative/destructive procedures for, 279–280, **307–317, 335–342**
 central processing of, 271–272
 deep brain stimulation for, **343–357**
 epidemiology of, 269
 experimental models for, 270–271
 functional anatomy of, **257–268**
 functional imaging in, **269–288**

Chronic (*continued*)

- brain regions involved in, 272–274
 - brain stem, 274, 276
 - cognitive modulation of, 276–278
 - emotional modulation of, 276–278
 - future studies of, 281
 - in ablative target identification, 279–280
 - in allodynia, 278–279
 - in drug development, 280
 - in hyperalgesia, 278–279
 - in treatment efficacy evaluation, 280–281
 - significance of, 272
 - spinal cord, 274, 276
 - intrathecal methods for, **289–296**
 - perception of, 271–272
 - spinal cord stimulation for, **297–306**
 - trigeminal neuralgia. *See* Trigeminal neuralgia.
 - versus nociception, 269–270
- Cingulotomy, for chronic pain, 338
- Circumferential decompression, in metastatic spine disease, 554–558
- Clarus neuroendoscopes, 26
- Clodronate, for metastatic spine disease, 531–532, 551
- Clonazepam, for trigeminal neuralgia, 319–320
- Clonidine, for intrathecal analgesia
- neostigmine with, 293–294
 - opioids with, 291–292
- Cluster headache, deep brain stimulation for, 345
- Coagulation, endoscopic equipment for, 27–28
- Codman & Shurtleff neuroendoscopes, 26
- Cognitive modulation, of pain experience,
- functional imaging in, 276–278
- Coils, for embolization, of metastatic spinal tumors, 393
- Colloid cysts, endoscopic removal of, 4, 103–106
- Communicating arteries, posterior, injury of, in third ventriculostomy, 69–70
- Complex regional pain syndrome, spinal cord stimulation for, 302
- Computed tomography
- in arachnoid cysts, 11
 - in extralemniscal myelotomy, 314–315
 - in metastatic spine disease, 369, 381–388
 - in CyberKnife radiosurgery, 495
 - in lateral extracavitary approach, 437–438
 - in pain evaluation, 516
 - sacral, 454
 - in percutaneous cordotomy, 307–311
 - in peripheral nerve tumors, 135
- Computer optimization, of intensity-modulated radiotherapy, for metastatic spine disease, 482–483
- Cook & Codman, cauterization equipment of, 27–28
- Copocephaly, 39
- Cordotomy, for chronic pain, 336
- neuropathic, 238–239
 - percutaneous, 307–311
 - versus deep brain stimulation, 348
- Corpus callosum
- agenesis of, 39, 42
 - developmental anatomy of, 34–35
- Corticosteroids, for metastatic spine disease, 516–517, 551
- before lateral extracavitary procedure, 427
 - postoperative, 450
- Costotransversectomy, for metastatic disease, 429–430
- Cowden syndrome, physical examination in, 127
- Cranial neuropathy, intracranial ablative procedures for, 336–338
- Craniopharyngioma, versus arachnoid cyst, 11–12
- Cryosurgery, for embolization, in metastatic spine disease, 397
- CSF. *See* Cerebrospinal fluid.
- CyberKnife, for metastatic spine disease
- contraindications to, 495
 - description of, 492–493
 - face mask and fiducial placement in, 495–496
 - indications for, 493–495
 - overview of, 495
 - positioning for, 493
 - treatment delivery with, 498–499
 - treatment planning for, 496–498
 - versus frame-based methods, 492
- Cyst(s)
- arachnoid. *See* Arachnoid cysts.
 - choroidal, of lateral ventricle, 39–40
 - colloid, endoscopic removal of, 4, 103–106
 - Dandy Walker, 43
 - ependymal, of lateral ventricle, 39–40
 - epidermoid, surgery for, outcomes of, 180–181, 186–187
 - ganglion, 226
 - case study of, 246

surgery for, outcomes of, 180–181, 186–187
 nerve, 226
 solitary, drainage of, 88–89

D

Dandy classification, of hydrocephalus, 45

Dandy Walker cysts, 43

Decompression

microvascular, for trigeminal neuralgia, 326–329
 of spinal cord, in metastatic disease
 cervical, 413–424
 circumferential, 554–558
 laminectomy in, 552–553, 556
 posterior approaches to, 425–435
 posterolateral approaches to, 427–432
 radiotherapy for, 474

Decq Neuro-Endoscope, 23–24

Deep brain stimulation, for pain, **343–357**

complications of, 351
 history of, 343–344
 indications for, 345–346
 outcomes of, 351–352
 pain classification and, 344–345
 patient selection for, 345–346
 pulse generator for, 351
 targets for, 346–347
 team approach to, 346
 technique for, 349–351
 trial, 351
 versus other pain interventions, 347–349

Demyelination, in spinal cord radiotherapy, 470–471

Dermatomes, in peripheral nerve tumors, evaluation of, 131

Desflurane, for metastatic spine disease surgery, 537

Desmoid tumors

brachial plexus, 244–246
 surgery for, outcomes of, 181, 187

Dexamethasone, for metastatic spine disease, 551

Diverticula, of lateral ventricle, 39

DNA, radiotherapy effects on, 467–468

Dorsal column, postsynaptic, in pain pathway, 259

Dorsal horn, in pain pathway, 258

Dorsal median sulcus mapping, for monitoring, in metastatic spine disease surgery, 539

Dorsal root entry lesion

for chronic pain, 335–336
 for neuropathic pain, 238

Dorsomedial nuclei, thalamic, destruction of, for chronic pain, 337–338

Doxorubicin, for metastatic spine disease, 531

Droperidol, for intrathecal analgesia, 294

Dumbbell tumors, of spine, 217–221

Dysesthesia, in peripheral nerve tumors, 125

E

Electrical stimulation

deep brain. *See* Deep brain stimulation.
 spinal cord. *See* Spinal cord, stimulation of.
 transcutaneous nerve, for neuropathic pain, 236

Electrocauterization, equipment for, 27–28

Electrodes, for spinal cord stimulation, 298–299

Electromyography, in peripheral nerve tumors, 137, 139, 141–142

Elephantiasis neuromatosa, 160

Embolization, of metastatic spinal tumors, **391–399**

agents for, 392–393
 anesthesia for, 393–394
 complications of, 397
 contraindications to, 392
 for intraoperative blood loss reduction, 394–395
 for palliation, 395–397
 goals of, 394
 success of, 394
 superselective, 394
 technical considerations in, 391–394
 timing of, 394
 versus other devascularization procedures, 397

Embryology, of ventricular system, 33–36

Emotional modulation, of pain experience, functional imaging in, 276–278

Endocrine disorders, in third ventriculostomy, 64

End-of-life care, of metastatic spine disease, pain management in, 522

Endometriosis, of sciatic nerve, 230

Endoscopy

- equipment for, **19–31**
- for arachnoid cysts, **9–17**
- for cancer, **95–109**
- for hydrocephalus, with loculated ventricles, **83–93**
- for metastatic spine disease, 461–462
- history of, **1–7**
- principles of, **19–31**
- third ventriculostomy. *See* Third ventriculostomy, endoscopic.
- ventricular anatomy for, **33–44**

Ependymal cysts, of lateral ventricle, 39–40

Epidermoid cysts, surgery for, outcomes of, 180–181, 186–187

Epithelioid malignant peripheral nerve sheath tumors, 164

Equipment, endoscopic, **19–31**

- cameras, 21
- fiberoptic, 19–20, 25–26
- for arachnoid cyst endoscopy, 12–15
- for coagulation, 27–28
- for CSF entrapment, 87–88
- for shunt placement, 27
- for third ventriculostomy, 60–61, 71
- history of, 19–20
- instruments, 28–29
- lasers, 29, 62–63
- light sources for, 20–21
- optic angles in, 20
- peel-away catheter, 22
- rigid, 19, 22–26
- scope holders, 29
- syringomyeloscope, 27
- video monitors, 21–22

Estramustine, for metastatic spine disease, 531

Ethanol, for embolization, in metastatic spine disease, 397

Extralemniscal myelotomy, for chronic pain, 314–315

F

Failed back surgery syndrome, spinal cord stimulation for, 302–303

Fascicular mapping, in intraneural dissection, 167–168

Fenestration

- of arachnoid cyst, 12–16
- of multiloculated ventricles, 89–90

Fentanyl, for pain, in metastatic spine disease, 517

Fiberoptic endoscopes, 19–20, 25–26

Fiducials, in CyberKnife treatment, 495–496

Flutamide, for metastatic spine disease, 531

Fogarty balloon, for endoscopy, 28

Foramen of Monro, anatomy of, 35–36

Foraminal nerve tumors, surgery for, 171–174

Forceps, for endoscopy, 28

Fornix, anatomy of, 58

Fourth ventricle

- anatomy of, 42–43
- CSF entrapment in, 84–86, 89
- malformations of, 43–44

Fractures, in metastatic spine disease, 367–368, 375–378, 530

G

Gaab Neuro-Endoscope, 23–24

Gabapentin

- for pain
 - in metastatic spine disease, 518–519
 - neuropathic, 235
- for trigeminal neuralgia, 320–321

Gamma knife stereotactic radiosurgery

- for hypophysectomy, 340
- for thalamotomy, 339
- for trigeminal neuralgia, 331–332

Gamma-aminobutyric acid, increase of, in spinal cord stimulation, 303

Ganglion cell tumors, paraspinal, 218

Ganglion cysts, 226

- case study of, 246
- surgery for, outcomes of, 180–181, 186–187

Ganglioneuroblastomas, paraspinal, 218

Ganglioneuromas

- paraspinal, 218
- pathology of, 162–163

Ganglioneuromatosis, intestinal, in multiple endocrine neoplasia, 226

Gastrointestinal symptoms, in peripheral nerve tumors, 126

Gelfoam, for embolization, of metastatic spinal tumors, 393

- Genetic factors, in neurofibromatosis
 - type 1, 149–150, 209–211
 - type 2, 152–153
- Glandular malignant peripheral nerve sheath tumors, 164
- Glial-derived neurotrophic factor, for intrathecal analgesia, 294–295
- Glioblastoma multiforme, case study of, 243–244
- Glycerol chemoneurolysis, for trigeminal neuralgia, 324–326
- Granular cell tumors, surgery for, outcomes of, 187–188

H

- Hamartoma(s)
 - lipofibromatous, 229–230
 - multiple, 127
- Harrington hooks and rods, with
 - polymethylmethacrylate cement, for metastatic spine disease, 416–417
- Hartel technique, for radiofrequency thermocoagulation, 322–324
- Headache
 - cluster, deep brain stimulation for, 345
 - in arachnoid cyst, 10
 - in slit ventricle syndrome, shunt removal in, third ventriculostomy for, 53–54
- Hemangiomas, surgery for, outcomes of, 181
- Hemangiopericytomas, surgery for, outcomes of, 181
- Hematoma, subdural, in third ventriculostomy, 68
- Hemorrhage
 - in arachnoid cyst endoscopy, 16
 - in third ventriculostomy, 63, 69–70
 - intraventricular
 - CSF entrapment in, 85–86
 - hydrocephalus in, third ventriculostomy for, 52
 - subarachnoid, hydrocephalus in, third ventriculostomy for, 52
- Heterotopic ossification, of peripheral nerve, 226–227
- Hippocampus, developmental anatomy of, 33
- Holoneural canal dilatation, in hydrocephalus, 85
- Holoprosencephaly, 38
- Hormonal therapy, for metastatic spine disease, 530–531
- Hydranencephaly, 38–39
- Hydrocephalus
 - communicating, third ventriculostomy
 - contraindicated in, 47–48
 - Dandy classification of, 45
 - double compartment, 85
 - etiology of, third ventriculostomy outcome and, 73, 78
 - hydromyelic, 85
 - in aqueduct of Sylvius occlusion, 49–51
 - in arachnoid cyst, 10
 - in brain tumors, 51–52
 - in fourth ventricle malformations, 43–44
 - in infants, third ventriculostomy for, 52–53
 - in intracranial hemorrhage, third ventriculostomy for, 52
 - in lateral ventricle malformations, 38–40
 - in third ventricle malformations, 41–42
 - isolated compartments in, **83–93**
 - multiloculated, 89–90
 - postinflammatory, 85–86
 - shunt-related, 83–85
 - solitary cysts in, 88–89
 - treatment of, 86–91
 - occlusive, in third ventriculostomy, 63
 - secondary, endoscopic treatment of, 96–99
 - third ventriculostomy for. *See* Third ventriculostomy.
- Hydronephrosis, in peripheral nerve tumors, 126
- Hyperalgesia
 - in neuropathic pain, 234
 - neuroimaging of, 278–279
- Hypercalcemia, in metastatic spine disease, 530
- Hyperesthesia, in peripheral nerve tumors, 125
- Hyperpigmentation, in neurofibromatosis, 145, 147, 151–152
- Hyperplastic nerve lesions, 228–229
- Hypertension
 - in neurofibromatosis type 1, 209
 - intracranial, endoscopic treatment of, 3
- Hypertrophic inflammatory neuropathy, 228–229
- Hypesthesia, in peripheral nerve tumors, 125
- Hypophysectomy, for chronic pain, 340
 - in metastatic spine disease, 520
- Hypothalamus
 - anatomy of, 40–41, 58

Hypothalamus (*continued*)

- injury of, in third ventriculostomy, 64, 68
- stimulation of, for pain management, 347, 350–351

I

-
- Ibandronate, for metastatic spine disease, 532
 - Immobilization, for intensity-modulated radiotherapy, 484–485
 - Infant(s), hydrocephalus in, third ventriculostomy for, 52–53
 - Infections
 - CSF entrapment in, 85–86
 - nerve lesions in, 227–228
 - Inflammation, CSF entrapment in, 85–86
 - Inflammatory nerve lesions, 227
 - Instruments, for endoscopy, 28–29
 - Intensity-modulated radiation therapy. *See* Radiotherapy, intensity-modulated.
 - Interdigital neuritis (Morton's neuroma), 226
 - Internal capsule, stimulation of, 349–350
 - Internal fixation, with decompressive laminectomy, for metastatic spine disease, 427
 - Intestinal ganglioneuromatosis, in multiple endocrine neoplasia, 226
 - Intracranial hypertension, endoscopic treatment of, 3
 - Intraneural dissection technique, 167–168
 - Intrathecal analgesia, **289–296**
 - agents for, 291
 - combination, 291–294
 - experimental, 294–295
 - single, 291
 - drug pumps for, 238
 - goals of, 290–291
 - literature review of, 289–290
 - pharmacokinetics and pharmacodynamics of, 291
 - scientific basis for, 289
 - versus deep brain stimulation, 348
 - Intrathoracic nerve sheath tumors, surgery for, 174
 - Intraventricular drug delivery, versus deep brain stimulation, 348
 - Intraventricular hemorrhage

CSF entrapment in, 85–86

hydrocephalus in, third ventriculostomy for, 52

K

-
- Ketamine, for intrathecal analgesia, opioids with, 293
 - Kidney dysfunction, in peripheral nerve tumors, 126
 - Knott rods, with polymethylmethacrylate cement, for metastatic spine disease, 417
 - Kölliker-Fuse nucleus, in pain pathway, 261
 - Kyphoplasty, for metastatic spine disease, percutaneous, 408, 460–461

L

-
- Laminectomy, for metastatic spine disease, 403–404, 426–427, 552–553, 556
 - Lamotrigine, for trigeminal neuralgia, 320
 - Laparoscopy, for thoracic spine metastatic disease, 462
 - Lasers, for endoscopy, 29, 62–63
 - Lateral extracavitary approach, to metastatic spine disease, 431–432, **437–441**
 - Lateral ventricle
 - anatomy of, 36–38
 - CSF entrapment in, 84
 - malformations of, 38–40
 - Leg pain, spinal cord stimulation for, 302–303
 - Leprosy, nerve lesions in, 227–228
 - Leptomeningeal disease, 386
 - Lidocaine, for pain, in metastatic spine disease, 519
 - Light sources, for endoscopy, 20–21
 - Linear accelerator, for metastatic spine disease radiotherapy, 407–408, 483. *See also* CyberKnife.
 - Lipofibromatous hamartomas, 229–230
 - Lipomas, surgery for, outcomes of, 187
 - Local anesthetics, for intrathecal analgesia, opioids with, 292–293
 - Localized hypertrophic neuropathy, 179–180, 228–229

Loculations

- CSF entrapment in, **83–90**
- of fourth ventricle, 43
- of lateral ventricle, 40

Locus ceruleus, in pain pathway, 261

Longstanding overt ventriculomegaly of the adult, 50–51

Louisiana State University Health Sciences

- Center, peripheral nerve tumor surgery outcomes at, **177–192**
- malignant, 180, 185–186, 190
- neural sheath, 177–180, 182–185
- nonneural sheath, 177–178, 180–181, 186–190

Lumbar interbody fusion, posterior, minimally invasive, for metastatic disease, 463

Lumbar radiculitis, spinal cord stimulation for, 302

Lumbar spine, metastatic disease of

- biomechanics of, 377–378
- epidemiology of, 511
- thoracoscopic vertebrectomy for, 462

Lung carcinoma, metastatic to spine, medical management of, 533

Lymphangiomas, surgery for, outcomes of, 188

M

Magnetic resonance angiography, in peripheral nerve tumors, 137

Magnetic resonance imaging

- functional
 - in allodynia, 278
 - in pain studies, 274–276, 279–281
- in aqueduct of Sylvius occlusion, 50
- in arachnoid cysts, 10–11
- in malignant peripheral nerve sheath tumors, 204
- in metastatic spine disease, 369–370, 381–388
 - for embolization planning, 392
 - for lateral extracavitary approach, 438
 - for pain evaluation, 516
 - for radiotherapy planning, 473
- sacral, 454
- in neurofibromatosis type 2, 152–153
- in paraspinal nerve sheath tumors, 219
- in peripheral nerve tumors, 135–140, 194
- in third ventriculostomy outcome assessment, 77, 79

Magnetic resonance neurography, in peripheral nerve tumors, 135

Magnetic resonance spectroscopy, in chronic pain, 279

Malignant epidural spinal cord compression, pain in. *See* Pain, in metastatic spine disease.

Malignant peripheral nerve sheath tumors, 129, **203–216**

- biologic therapy for, 208–209
- case study of, 249
- chemotherapy for, 149, 208
- definition of, 203
- epidemiology of, 203–204
- epithelioid, 164
- glandular, 164
- grading of, 206
- history in, 204
- imaging in, 204–205
- in neurofibromatosis, 146–149, 209–211
- motor examination in, 129
- occupational therapy for, 208
- paraspinal, 218, 221
- pathology of, 163–164, 205–206
- physical examination in, 204
- physiotherapy for, 208
- prognosis for, 208
- psychotherapy for, 208
- radiotherapy for, 207–208
- rhabdomyosarcomatous, 164
- risk factors for, 203–204
- surgery for, 206–207
 - outcomes of, 180, 185–186
 - principles of, 170–171
- treatment of, 149, 205–209
- variants of, 163–164

Malignant peripheral nonneural sheath tumors, surgery for, outcomes of, 178

Mamillary bodies, anatomy of, 40

Medial thalamotomy, for chronic pain, 337–338

Melanotic schwannomas, 159

Melzack and Wall gate control theory, 297

Meningiomas, in neurofibromatosis, 151–152

Meningitis, carcinomatous, 386

Merlin gene, mutations of, 152, 159

Mesencephalic tractotomy, for chronic pain, 337

Metastasis

- surgery for, outcomes of, 190
- to brachial plexus, 249
- to spine. *See* Metastatic spine disease.

Metastatic spine disease

- angiography in, 370, 426, 438
- biomechanics of, **375–380**
 - clinical applications of, 378–379
 - regional nuances in, 376–378
- biopsy in, 370–371
- bone scan in, 368, 381, 385
- classification of, 365
- clinical features of, 366–367, 453–454, 529–530. *See also* Pain, in metastatic spine disease.
- computed tomography in, 369, 381–388
 - in pain evaluation, 516
 - sacral, 454
- diagnosis of, 454, 459–460, 529
- differential diagnosis of, 512
 - extradural, 385
 - intradural, 387–388
 - intramedullary, 388
 - sacral, 454
- embolization of, **391–399**
- epidemiology of, 365, 401, 425, 453, 511, 549–550
- epidural, 512
- evaluation of, in pain, 513–516
- extradural, radiology of, 382–385
- extramedullary, radiology of, 385–388
- from breast carcinoma, medical management of, 532
- from lung carcinoma, medical management of, 533
- from multiple myeloma, medical management of, 533–534
- from prostate carcinoma, medical management of, 532–533
- history in, 366–367
- hypervascular, embolization of, 391–399
- intradural, radiology of, 385–388
- intramedullary, radiology of, 388
- magnetic resonance imaging in. *See* Magnetic resonance imaging, in metastatic spine disease.
- medical management of, **529–536**
 - bisphosphonates in, 406–407, 531–532, 551–552
 - chemotherapy in, 406–407, 454–455, 531
 - diagnosis in, 529
 - hormonal, 530–531
 - new techniques in, 534
 - radiopharmaceuticals in, 531
 - versus tumor type, 532–534
- myelography in, 368–369, 381
- pain management in, **511–527**

- pathophysiology of, 365–366
- patterns of, 512
- physical examination in, 366–367
- radiobiology of, 467–471
- radiography in, 367–368, 381, 454, 516
- radiology of, **381–389**
- radiotherapy for. *See* Radiotherapy, for metastatic spine disease.
- sacral, **453–457**
- spinal distribution of, 366, 375–376
- surgical treatment of
 - anterior approaches to, **443–451**, 462–463
 - approaches to, 408–409
 - biomechanics of, 378–379
 - cervical, **413–424**
 - evidence-based, **549–564**
 - indications for, 404–406
 - minimally invasive, **459–465**
 - neuromonitoring during, **537–547**
 - posterior approaches to, **425–435**
 - minimally invasive, 463–464
 - procedures for, 408
 - radiosurgery. *See* Radiosurgery, for metastatic spine disease.
 - sacral, 455
- treatment of, **401–411**
 - chemotherapy in, 406–407, 454–455, 531, 551–552
 - clinical trials of, **549–564**
 - evolution of, 403–404
 - goals of, 401–403
 - radiotherapy in. *See* Radiotherapy, for metastatic spine disease.
 - sacral, 454
 - surgical. *See* Metastatic spine disease, surgical treatment of.

N-Methyl-D-aspartate antagonists, for intrathecal analgesia, opioids with, 293

N-Methyl-D-aspartate receptors, in pain pathway, 262

Micro-multileaf collimation, in intensity-modulated radiotherapy, 483

Microsurgery, endoscopic-assisted, for tumors, 106–107

Microvascular decompression, for trigeminal neuralgia, 326–329

Midazolam, for intrathecal analgesia, 294

Midbrain, pain perception in, 272–273

Midline myelotomy, for chronic pain, 336

Minimally invasive treatment, for metastatic spine disease, **459–465**
 biopsy, 459–460
 kyphoplasty, 408, 460–461
 vertebroplasty, 408, 460–461

MINOP Neuroendoscopy System, 23–25

Monitoring
 in endoscopy, video equipment for, 21–22
 intraoperative. *See* Neuromonitoring.

Mood, pain perception and, 278

Morphine
 effects of, functional imaging of, 280
 for intrathecal analgesia
 as single agent, 291
 baclofen with, 292
 clonidine with, 291–292
 local anesthetics with, 292–293
 N-methyl-D-aspartate antagonists with, 293
 neostigmine with, 293
 for pain
 in metastatic spine disease, 517
 neuropathic, 235

Morphine naloxone test, for pain classification, 345

Morton's neuromas, 226

Motor cortex stimulation
 for neuropathic pain, 237–238
 versus deep brain stimulation, 348–349

Motor deficits, in peripheral nerve tumors, 126, 128–130

Motor evoked potentials, transcranial, in metastatic spine disease surgery, 539–543

Mucosal neuromas, in multiple endocrine neoplasia, 228

Multileaf collimation, in intensity-modulated radiotherapy, 483

Multiple endocrine neoplasia, type IIb, hyperplastic nerve lesions in, 226

Multiple myeloma, metastatic to spine, medical management of, 533–534

MurphyScope, 26

Muscle(s), asymmetry of, in peripheral nerve tumors, 129

Mycobacterium leprae, in nerve lesions, 227–228

Myelography, in metastatic spine disease, 368–369, 381

Myelopathy, in spinal cord radiotherapy, 470–471

Myeloscopy, 4

Myelotomy, for chronic pain
 extralemniscal, 314–315
 midline, 336

Myoblastomas, surgery for, outcomes of, 187–188

Myocardial ischemia, pain in, spinal cord stimulation for, 300–301

Myositis ossificans, surgery for, outcomes of, 181, 188–189

N

Neck pain, in metastatic spine disease. *See* Pain, in metastatic spine disease.

Necrosis, in metastatic spine disease, 513

Neostigmine, for intrathecal analgesia
 clonidine with, 293–294
 opioids with, 293

Nerve(s)
 cysts of, 226
 implantation of, 116–117
 peripheral, tumors of. *See* Peripheral nerve tumors.

Nerve roots
 neurofibromatosis of, 148
 protection of, in paraspinal tumor removal, 219
 tumors of, surgery for, 171–174

Neuralgia, trigeminal. *See* Trigeminal neuralgia.

Neuritis
 in peripheral nerve tumors, 126
 interdigital (Morton's neuroma), 226

Neuritis ossificans, 226–227

Neuroablative procedures, for pain, in metastatic spine disease, 520

Neuroblastomas, paraspinal, 218

Neuroendoscopy. *See* Endoscopy.

Neurofibroma(s). *See also* Neurofibromatosis.
 malignant, surgery for, outcomes of, 180
 paraspinal, 218
 pathology of, 159–161
 surgery for, outcomes of, 178–179, 183–184

Neurofibromatosis, 145–155

- physical examination in, 127–132
- schwannomatosis type of, 153–154
- type 1, 145–150
 - case study of, 243–244, 247–249
 - clinical presentation of, 147–148
 - description of, 145–147
 - diagnosis of, 147
 - discrete lesions in, 146
 - genetic basis of, 149–150, 209–211
 - malignant peripheral nerve sheath tumors in, 164, 209–211
 - pathology in, 160
 - plexiform, 146–149, 160
 - case study of, 247–249
 - surgery for, 170–171
 - surgery for, 169–171, 183–184
 - treatment of, 148–149
 - versus schwannomatosis, 153–154
- type 2, 150–153
 - description of, 150–151
 - diagnosis of, 151–152
 - genetic factors in, 152–153
 - schwannomas with, 159
 - treatment of, 153
 - versus schwannomatosis, 154

Neurofibromin gene, mutations of, 150, 209–210

Neurofibrosarcomas. *See* Malignant peripheral nerve sheath tumors.

Neurologic disorders, in metastatic spine disease

- clinical features of, 514–515
- evaluation of, 515–516
- pathogenesis of, 512–513
- sacral, 453

Neurolysis

- for pain, in metastatic spine disease, 520
- for trigeminal neuralgia
 - glycerol, 324–326
 - percutaneous, 321–322

Neuroma(s)

- formation of, 234
- Morton's, 226
- mucosal, 228
- palisaded encapsulated, 228
- resection of, for neuropathic pain, 235–236
- traumatic, 225–226

Neuroma in continuity, surgery for, 114–115

Neuromodulation, spinal cord stimulation as, 297

Neuromonitoring, during metastatic spine disease surgery, **537–547**

anesthesia, 537

- dorsal median sulcus mapping in, 539
- somatosensory evoked potentials in, 538–539
- spinal cord mapping in, 543–545
- transcranial motor evoked potentials in, 539–543

Neuromuscular choristoma, 230

NeuroNavigational endoscopes, 26

Neuropathic pain, 233–241

- causes of, 270
- deep brain stimulation for, 344–345
- functional anatomy of, **257–268**
 - ascending pain pathways, 258–260
 - descending pain pathways, 260–261
 - pain pathway activation, 257–258
 - sensitization in, 261–263
- management of
 - ablative procedures for, 238–239
 - anticonvulsants for, 235
 - antidepressants for, 235
 - intrathecal drug pumps for, 238
 - motor cortex stimulation for, 237–238
 - neuroma resection for, 235–236
 - opioids for, 235
 - peripheral nerve stimulation for, 236–237
 - spinal cord stimulation for, 236
 - transcutaneous electrical nerve stimulation for, 236
 - pathophysiology of, 233–234
 - spinal cord stimulation for, 301–302

NeuroPen endoscope, 26

Neuropeptides, in pain transmission, 258, 262

Neurotization, 115–116

Neurotrophin-3 antisense oligonucleotide, for intrathecal analgesia, 294

Neuroview endoscope, 25–26

NF1 gene, mutations of, 150, 209–210

Nociception. *See also* Neuropathic pain, functional anatomy of.
versus pain, 269–270

Nociceptive pain, deep brain stimulation for, 344

Nonsteroidal anti-inflammatory drugs, for pain, in metastatic spine disease, 518–519

Nortriptyline, for pain, in metastatic spine disease, 519

Novalis Shaped-Beam Surgery unit, for metastatic spine disease radiosurgery, **503–509**

Nucleotomy, trigeminal, 311–314

Nucleus caudalis, destruction of, for trigeminal neuralgia, 311–314

O

Occipital pole, anatomy of, 38

Occupational therapy, for malignant peripheral nerve sheath tumors, 208

Opioids

effects of, functional imaging of, 280

for intrathecal analgesia

as single agents, 291

baclofen with, 292

clonidine with, 291–292

local anesthetics with, 292–293

N-methyl-D-aspartate antagonists with, 293

neostigmine with, 293

for pain

in metastatic spine disease, 517–519, 522–524

neuropathic, 235

Orthotics, in metastatic spine disease, 520

Ossification, heterotopic, of peripheral nerve, 226–227

Osteochondromas, surgery for, outcomes of, 189–190

Osteolysis, in metastatic spine disease, 367

Osteoprotegerin, for metastatic spine disease, 534

Oxcarbazepine, for trigeminal neuralgia, 319–321

P

Pacinian neuromas, 225–226

Pain

chronic. *See* Chronic pain.

in metastatic spine disease, 366–367, **511–527**, 529–530

differential diagnosis of, 512

evaluation of, 513–516

management of, 516–524

in pediatric patients, 521–522

in terminal illness, 522

neuroablative procedures in, 520

ongoing, 518–521

palliative care in, 429–431, 454, 474, 523

pharmacologic, 516–520, 523–524

psychologic interventions in, 520–521

radiotherapy in, 517

rehabilitation in, 520

surgical, 517–518, 520

variables affecting, 521

with concurrent substance abuse, 522

pathogenesis of, 512–513

sacral, 453–454

types of, 401, 403

undertreatment of, 511

in peripheral nerve tumors, 126

neuropathic. *See* Neuropathic pain.

“Paintbrush” block, in metastatic spine disease, 369

Palisaded encapsulated neuromas, 228

Palliation therapy, for metastatic spine disease

embolization in, 395–397

pain management in, 523

radiotherapy in, 474

sacral, 454

Pamidronate, for metastatic spine disease, 532

Pancoast tumors, surgery for, 449

Parafascicular nuclei, thalamic, destruction of, for chronic pain, 337–338

Paraspinal nerve sheath tumors, **217–223**

classification of, 217–218

clinical presentation of, 218

imaging in, 218–219

incidence of, 217

treatment of, 219–221

Paresthesia, production of, in deep brain stimulation, 346–347, 349–351

Pathologic fractures, in metastatic spine disease, 367–368, 375–378, 530

Patient-controlled analgesia, in metastatic spine disease, 517

Peacock system, in intensity-modulated radiotherapy, 483

Pediatric patients, metastatic spine disease in, pain management in, 521–522

Pedicle screw fixation, percutaneous, for metastatic disease, 463

Pediclectomy, for metastatic spine disease, 428–429

Pelvis, peripheral nerve tumors of, 126

Percutaneous procedures

balloon compression, for trigeminal neuralgia, 326

Percutaneous (*continued*)

- cordotomy, for chronic pain, 307–311
- kypoplasty, for metastatic spine disease, 408, 460–461
- lumbar spine fixation, for metastatic disease, 463
- neurolysis, for trigeminal neuralgia, 321–322
- pedicle screw fixation, for metastatic disease, 463
- radiofrequency, for trigeminal neuralgia, 322–324
- vertebroplasty, for metastatic spine disease, 408, 460–461

Periaqueductal gray matter

- in pain pathway, 257, 259–260
- stimulation of, for pain management, 347, 350

Perineuromas, pathology of, 161–162

Peripheral nerve sheath tumors

- malignant. *See* Malignant peripheral nerve sheath tumors.
- paraspinal, **217–223**
- surgery for, outcomes of, 179

Peripheral nerve stimulation, for neuropathic pain, 236–237

Peripheral nerve surgery, history of

- bridging nerve gaps, 112–114
- carpal tunnel syndrome, 117–118
- direct implantation, 116–117
- early, 110–111
- neuroma in continuity, 114–115
- neurotization, 115–116
- primary repair, 111–112
- sutureless repair, 112
- thoracic outlet syndrome, 117
- tumors, 118–119

Peripheral nerve tumors

- asymmetric, 168
- asymptomatic, 125
- biopsy in, 194–196, 205
- case studies of, **243–251**
- choristoma, 230
- clinical presentation of, **125–132**
- diagnosis of, **133–144**
 - complications of, 193–196
- distribution of, 128
- electrophysiologic testing in, 137, 139, 141–142
- endometriosis, 230
- history taking in, 125–127, 133–134, 193–194
- hyperplastic, 228–229
- imaging in, 135–140
 - errors in, 194

infectious, 227–228

inflammatory, 227

lipofibromatous, 229–230

neurofibromatosis as. *See* Neurofibromatosis.neuropathic pain in, **233–241**nonneoplastic, **225–232**

palpation of, 128–129

pathology of, **157–166**

- ganglioneuroma, 162–163

- malignant, 163–164

- neurofibroma, 159–161

- perineuroma, 161–162

- schwannoma, 157–159

- physical examination in, 127–132, 134–135

reactive, 225–227

surgery for

- approaches to, 171–175

- extremity tumors, 171

- foraminal tumors, 171–174

- intrathoracic nerve sheath tumors, 174

- retroperitoneal nerve sheath tumors, 174–175

- complications of, **193–202**

- decision-making in, 196–197

- errors in, 196–202

- exposure in, 169

- fascicular mapping in, 167–168

- goals of, 169

- history of, **110–124**

- in neuropathic pain control, 238–239

- indications for, 196–197

- inspection during, 167–168

- malignant nerve sheath, 206–207

- neurofibromatosis, 148–149, 152–153

- nonneoplastic, 225–232

- nonneural sheath, 177–178, 180–181, 186–190

- outcomes of, **177–192**

- malignant, 180, 185–186, 190

- neural sheath, 177–180, 182–185

- nonneural sheath, 177–178, 180–181, 186–190

- principles of, **167–175**

- malignant nerve sheath tumor removal, 170–171

- neurofibromatosis type 1, 169–171

- plexiform neurofibroma removal, 170

- resection, 168–169

- team approach to, 201–202

- techniques for

- asymmetric tumor removal, 168

- intraneural dissection, 167–168

Peripheral sensitization, in neuropathic pain, 261–262

Peripheral vasculopathy, pain in, spinal cord stimulation for, 299–300

Periventricular gray matter, stimulation of, for pain management, 347, 350

Peroneal nerve, common, ganglion cyst of, 246

Phenytoin, for trigeminal neuralgia, 320

Pheochromocytoma, in neurofibromatosis type 1, 209

Physical therapy
for malignant peripheral nerve sheath tumors, 208
for metastatic spine disease, 520

Pituitary gland, ablation of, for chronic pain, 340

Placebo effects, in pain perception, 277–278

Plaques, in neurofibromatosis, 151

Plate stabilization, for cervical spine metastatic disease, 418–423

Plexiform neurofibromatosis, 146–149, 160
case study of, 247–249
surgery for, 170–171

Plexiform schwannomas, 159

Pneumocephalus, in third ventriculostomy, 67

Polymethylmethacrylate cement, for metastatic spine disease, 408, 415–423, 460

Polyvinyl alcohol particles, for embolization, of metastatic spinal tumors, 392–393

Porencephaly, 39

Positron emission tomography
in malignant peripheral nerve sheath tumors, 204–205
in pain studies, 280–281
in peripheral nerve tumors, 194

Postembolization syndrome, 397

Posterior approaches, to metastatic spine disease, **425–435**
anterior approaches with, 445, 449
costotransversectomy, 429–430
decompressive laminectomy, 426–427
direct trajectory, 426–427
goals of, 425–426
indications for, 426
lateral extracavitary/lateral parascapular, 431–432, **437–441**

minimally invasive, 463–464
posterolateral, 427–432
transpedicular, 428–429

Posterolateral approaches, to metastatic spine disease, 427–432

Postsynaptic dorsal column, in pain pathway, 259

Precentral stimulation, versus deep brain stimulation, 348–349

Pretectal nucleus, in pain pathway, 261

Prostate carcinoma, metastatic to spine, medical management of, 532–533

Prosthesis, with polymethylmethacrylate cement, for metastatic spine disease, 417–418

Pseudo-onion bulbs, in perineuroma, 162

Pseudotumor, inflammatory, of nerve, 227

Psychologic interventions, for metastatic spine disease, 520–521

Psychotherapy, for malignant peripheral nerve sheath tumors, 208

Pulse generators, for spinal cord stimulation, 298

R

Radicular pain, in metastatic spine disease, 401, 403, 453–454, 513

Radiculitis, lumbar, spinal cord stimulation for, 302

Radiculopathy, in neurofibromatosis, 148

Radiobiology, principles of, 467–471

Radiofrequency
for cordotomy, 309
for percutaneous thermocoagulation
for metastatic spine disease, 461
for trigeminal neuralgia, 322–324

Radiography, in metastatic spine disease, 367–368, 381
in pain evaluation, 516
sacral, 454

Radiology, of metastatic spine disease, **381–389**.
See also specific modalities.

Radiopharmaceuticals, for metastatic spine disease, 531

Radiosurgery
CyberKnife for. *See CyberKnife.*
for chronic pain, 338–340

Radiosurgery (*continued*)
 for hypophysectomy, 340
 for metastatic cancer pain, 340
 for metastatic spine disease, 491–492
 Novalis Shaped-Beam Surgery unit for, **503–509**
 principles of, 474–477
 for thalamotomy, 339
 for trigeminal neuralgia, 331–332, 339–340

Radiotherapy. *See also* Radiosurgery.
 for malignant peripheral nerve sheath tumors, 149, 207–208
 for metastatic spine disease
 biologically effective dose in, 473
 biology of, 467–471
 clinical trials of, 558–559
 dose fractionation effects in, 471–473
 in pain management, 517
 indications for, 404
 intensity-modulated, **481–490**
 planning for, 473
 repeat spinal cord irradiation in, 471
 results of, 403–404, 473–474
 sacral, 454–455
 standard, 473–474
 techniques for, 407–408
 versus radiosurgery, 491
 for paraspinal tumors, 221
 intensity-modulated, for metastatic spine disease, **481–490**
 accuracy of, 483–484
 computer optimization for, 482–483
 delivery of, 483
 historical perspective of, 481–482
 immobilization for, 484–485
 indications for, 488
 planning for, 485–487

Raphe nuclei, in pain pathway, 261

Reactive lesions, of peripheral nerves, 225–227

Reflex(es), in peripheral nerve tumors, evaluation of, 131

Reflex sympathetic dystrophy, spinal cord stimulation for, 302

Rehabilitation, in metastatic spine disease, 520

Renal cell carcinoma, metastatic to spine, embolization of, 391–397

Reticular formation, in pain pathway, 261

Retromastoid microvascular decompression, for trigeminal neuralgia, 326–329

Retroperitoneal approach, to metastatic spine disease, 448

Retroperitoneal nerve sheath tumors, surgery for, 174–175

Rhabdomyosarcomatous malignant peripheral nerve sheath tumors, 164

Rhizotomy
 for pain, in metastatic spine disease, 520
 for trigeminal neuralgia, 329–331

Rigid endoscopes, 19, 22–26

Risedronate, for metastatic spine disease, 532

Robotic linear accelerator. *See* CyberKnife.

S

Sacral metastatic tumors, **453–457**
 anatomic considerations in, 453
 clinical presentation of, 453–454
 diagnosis of, 454
 imaging of, 454
 outcome of, 455–456
 treatment of, 454–455

Sarcoidosis, nerve lesions in, 227

Schizencephaly, 38

Schwann cells, in neurofibromas, 160

Schwannoma(s)
 case study of, 243
 malignant, surgery for, outcomes of, 180
 paraspinal, 218, 220
 pathology of, 157–159
 surgery for, outcomes of, 178–179, 182–183
 variants of, 159
 vestibular, in neurofibromatosis type 2, 150–153

Schwannomatosis, 153–154, 250–251

Schwannomin gene, mutations of, 152

Sciatalgia, spinal cord stimulation for, 302–303

Sciatic nerve, endometriosis of, 230

Scintigraphy. *See* Bone scan.

Seizures, in arachnoid cyst, 10

Sensitization, in neuropathic pain, 261–263

Sensory deficits, in peripheral nerve tumors, 125, 130–131

Sensory examination, in metastatic spine disease, 516

Shunt

- CSF entrapment due to, 83–85
- endoscopic equipment for, 27
- existing, third ventriculostomy outcome with, 76
- for arachnoid cyst, 15
- removal of, third ventriculostomy for, 53–54

Skin

- neurofibromas of, 147, 151, 160
- peripheral nerve tumor manifestations in, 127

Slit ventricle syndrome

- entrapped CSF in, 83–85
- shunt removal in, third ventriculostomy for, 53–54

Somatosensory evoked potentials, for monitoring, in metastatic spine disease surgery, 538–539

Spinal analgesia. *See* Intrathecal analgesia.

Spinal cord

- compression of, in metastatic disease
 - cervical, **413–424**
 - embolization for, 396
 - pain in. *See* Pain, in metastatic spine disease.
 - pathogenesis of, 512–513
 - posterior approaches to, 425–435
 - radiotherapy for, 474
- cordotomy of
 - for chronic pain, 336
 - for neuropathic pain, 238–239
- destructive/ablative procedures for, for chronic pain, **307–317**
 - cordotomy, 336
 - dorsal root entry lesions, 335–336
 - extralemniscal myelotomy, 314–315
 - midline myelotomy, 336
 - percutaneous cordotomy, 307–311
 - trigeminal tractotomy-nucleotomy, 311–314
- electrical stimulation of, for neuropathic pain, 236
- injury of, pain in, spinal cord stimulation for, 303
- mapping of, in metastatic spine disease surgery, 543–545
- neurofibromatosis of, 151
- pain perception in, functional imaging of, 274, 276
- radiation tolerance of, 469–471
- reirradiation of, 471
- stimulation of, **297–306**
 - complications of, 303–304

- for angina pectoris, 300–301
- for back pain, 302–303
- for leg pain, 302–303
- for neuropathic pain, 301–302
- for peripheral vasculopathy, 299–300
- for spinal cord injury pain, 303
- information sources for, 299
- rationale for, 297
- technique for, 298–299
- versus deep brain stimulation, 348

Spindle cells, in malignant peripheral nerve sheath tumors, 164

Spine, tumors of. *See also* Metastatic spine disease; Paraspinal nerve sheath tumors. in spinal canal, surgery for, 171–174

Spinomesencephalic tract, in pain pathway, 259

Spinothalamic tract

- in pain pathway, 258–259
- lesioning of, for chronic pain, 307–311

Steinmann pins, with polymethylmethacrylate cement, for metastatic spine disease, 416

Stereotactic techniques

- for cingulotomy, 338
- for deep brain stimulation, 349
- for radiotherapy. *See also* CyberKnife. versus intensity-modulated radiotherapy, 481
- mesencephalic tractotomy, 337
- radiosurgery, for trigeminal neuralgia, 331–332

Stimulation

- deep brain. *See* Deep brain stimulation.
- nerve, for neuropathic pain, 236
- spinal cord. *See* Spinal cord, stimulation of.

Strength, muscle, evaluation of, in peripheral nerve tumors, 130

Striatum, pain perception in, 272–273

Strontium 89, for metastatic spine disease, 531

Subarachnoid hemorrhage, hydrocephalus in, third ventriculostomy for, 52

Subdural hematoma, in third ventriculostomy, 68

Substance abuse, cancer pain management in, 522

Sympathetic nervous system, spinal cord stimulation effects on, 300

Syringomyeloscope, 27

T

- Tamoxifen, for metastatic spine disease, 530–531
- Taxanes, for metastatic spine disease, 531
- Telescopic Plate Spacer, for metastatic spine disease, 420–423
- Temporal horn, anatomy of, 38
- Terminal stages, of metastatic spine disease, pain management in, 522
- Thalamostriate vein, anatomy of, 37
- Thalamotomy, for chronic pain
 medial, 337–338
 radiosurgical, 339
- Thalamus
 anatomy of, 41
 in pain pathway, 259–261
 stimulation of, for pain management, 346–347, 349–350
- Therapeutic ratio, in radiotherapy, 468–469
- Thermocoagulation, radiofrequency
 for metastatic spine disease, 461
 for trigeminal neuralgia, 322–324
- Third ventricle
 anatomy of, 40–41, 59
 malformations of, 41–42
 endoscopy contraindicated in, 48–49
 small, endoscopy contraindicated in, 48–49
- Third ventriculostomy
 endoscopic
 anatomic considerations in, 57–59, 76–78
 approaches to, 59–60
 balloon dilatation in, 61
 complications of, 63–64, **67–72**
 asystole, 69
 avoidance of, 70–71
 bradycardia, 69
 cerebrospinal fluid leak, 67
 failure, 70
 intraoperative management of, 71
 periventricular injury, 68–69
 pneumocephalus, 67
 subdural hematoma, 68
 vascular, 69–70
 ventriculitis, 67–68
 dissection in, 61
 equipment for, 60, 71
 failure of, 70, 79
 for arachnoid cyst, 12
 for secondary hydrocephalus, 96–99
 goals of, 77
 history of, 3–4, 57
 patient selection for, **45–55**, 70–71
 anatomic considerations in, 45–47
 biophysical considerations in, 45–47
 contraindications, 47–49
 in aqueduct of Sylvius occlusion, 49–51
 in hemorrhage, 52
 in infant hydrocephalus, 52–53
 in programmed shunt removal, 53–54
 in tumors, 51–52
 positioning for, 68, 71
 postoperative management in, 71
 results of, **73–81**
 anatomic considerations in, 76–78
 assessment of, 77, 79
 clinical features and, 74–78
 factors affecting, 73–74
 failure, 79
 saline jet irrigation in, 61–62
 saline torch use in, 62
 stereotactic, 63, 79
 technique for, 60–63, 68–69, 98–99
 training for, 71
 trajectories for, 59–60
 with narrow ventricle, 68–69
 stereotactic, versus endoscopic procedure, 79
- Thoracic outlet syndrome, surgery for, 117
- Thoracic spine, metastatic disease of
 biomechanics of, 377–378
 epidemiology of, 511
- Thoracoabdominal approach, to metastatic spine disease, 447
- Thoracotomy, for nerve sheath tumors, 174, 221
- Tic douloureux. *See* Trigeminal neuralgia.
- Tinel's sign, in peripheral nerve tumors, 131
- Titanium interbody cage, for metastatic spine disease, 419–420
- Tomotherapy, in intensity-modulated radiotherapy, 483
- Tractotomy
 mesencephalic, 337
 trigeminal, 311–314
- Transcranial motor-evoked potentials, for monitoring, in metastatic spine disease surgery, 539–543
- Transcutaneous electrical nerve stimulation, for neuropathic pain, 236

- Transpedicular approach, to metastatic spine disease, 428–429
- Transthoracic approach, to metastatic spine disease, 447
- Traumatic neuromas, 225–226
- Tricyclic antidepressants, for pain
in metastatic spine disease, 519–520, 523–524
neuropathic, 235
- Trigeminal neuralgia, **319–334**
medical treatment of, 319–321
surgical treatment of, 321–332
microvascular decompression, 326–329
percutaneous balloon compression, 326
percutaneous glycerol chemoneurolysis, 324–326
percutaneous neurolysis, 321–322
percutaneous radiofrequency thermocoagulation, 322–324
radiosurgery, 331–332, 339–340
rhizotomy, 329–331
stereotactic radiosurgery, 331–332
tractotomy-nucleotomy, 311–314
- Trigone, anatomy of, 38
- Triton tumors, malignant, 164
- Tumor(s)
brachial plexus. *See* Brachial plexus, tumors of.
brain, endoscopy in, **95–109**
history of, 4
in biopsy, 100–101
in intraventricular tumor resection, 100–106
in microsurgery, 106–107
in secondary hydrocephalus, 51–52, 96–99
in ventriculoscopy, 96
metastatic. *See* Metastasis; Metastatic spine disease.
peripheral nerve. *See* Peripheral nerve tumors.

U

- Ulnar nerve compression, by angiolipoma, 247
- Ultrasonography, in third ventriculostomy, 63

V

- Valproic acid, for trigeminal neuralgia, 320
- Vasculopathy, peripheral, pain in, spinal cord stimulation for, 299–300
- Ventralis posteromedialis nuclei, stimulation of, 349–350

Ventricle(s). *See also specific ventricles.*

- anatomy of, **33–44**
cerebral aqueduct, 42
developmental, 33–36
fourth ventricle, 42–44
lateral ventricle, 36–40
third ventricle, 40–41, 59
- loculated
CSF entrapment in, **83–93**
multiloculated, 89–90
postinflammatory, 85–86
shunt-related, 83–85
solitary cysts in, 88–89
treatment of, 86–91
- fourth, 43
lateral, 40

Ventriculitis, in third ventriculostomy, 67–68

Ventriculomegaly, longstanding, of the adult, 50–51

Ventriculoscopy, for tumor evaluation, 4, 96

Ventriculostomy, third. *See* Third ventriculostomy.

Ventroposterolateral thalamic nuclei
in pain pathway, 258–261
stimulation of, 349–350

Verocay bodies, in schwannomas, 157–158

Vertebrae, metastasis to. *See* Metastatic spine disease.

Vertebrectomy, for metastatic spine disease
anterior approach to, 448
endoscopic, 408, 462
lateral extracavitary approach to, 431–432, **437–441**
posterior approaches to, 427–432

Vertebroplasty, for metastatic spine disease
anterior approach to, 448–449
cervical, **413–424**
percutaneous, 408, 460–461
posterior approaches to, 427–432

Vestibular schwannomas, in neurofibromatosis type 2, 150–153

Video monitors, for endoscopy, 21–22

Video-assisted thoracoscopic surgery, for metastatic spine disease, 461–462

Visceral symptoms, in peripheral nerve tumors, 125–126

von Recklinghausen disease. *See*
Neurofibromatosis, type 1.

W

Weinstein classification, of spinal fractures, in
metastatic disease, 378

“Winking owl” sign, in metastatic spine disease, 367

World Health Organization, analgesic ladder of,
for metastatic spine disease, 518

X

X syndrome, pain in, spinal cord stimulation for,
301

Z

Ziconotide, for intrathecal analgesia, 294

Zoledronic acid, for metastatic spine
disease, 532